Chemotherapy for high-risk early-stage endometrial cancer

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 1, 2007, Pages 42-47

  Kodama, Junichi ^a,b   Seki, Noriko ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Early stage; Endometrial cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; PIRARUBICIN; PLATINUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; ENDOMETRIUM CANCER; HISTOLOGY; HUMAN; INCIDENCE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; PRACTICE GUIDELINES; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 33846214695     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32801127b7     Document Type: Review

References (39)

1. Berek JS, Adashi EY, Hillard PA. Gynecology. Maryland: Lippincott Williams & Wilkins; 1996.
2. Announcements: FIGO stages - 1988 revision. Gynecol Oncol 1980; 35:125-127.
3. Gouge C, Bernhard S, Cloven NG. The impact of complete surgical staging on adjuvant treatment decisions in endometrial cancer. Gynecol Oncol 2004; 93:536-539.
4. Keys HM, Roberts JA, Brunetto VL. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744-751.
5. Creasmann WT, Morrow CP, Bundy BN. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 1987; 60:2035-2041.
6. Creutzberg CL, van Putten WL, Koper PC. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicenter randomized trial: PROTEC Study Group Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 35: 1404-1411.
7. Aalders J, Abeler V, Kolstad P. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980; 56:419-427.
8. Creutzberg CL, van Putten WLJ, Wárlaám-Rodenhuis CC. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: The Postoperative Radiation Therapy in Endometrial Carcinoma trial. J Clin Oncol 2004; 22:1234-1241.
9. Naumann RW, Higgins RV, Hall JB. The use of adjuvant radiation therapy by members of the society of gynecologic oncologists. Gynecol Oncol 1999; 75:4-9.
10. Shaeffer DT, Randall ME. Adjuvant radiotherapy in endometrial carcinoma. Oncologist 2005; 10:623-631.
11. Münstedt K, Grant P, Woenckhaus J. Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg Oncol 2004; 2:24.
12. Hirai M, Hirono M, Oosaki T. Adjuvant chemotherapy in stage I uterine endometrial carcinoma. Int J Gynecol Obstet 2002; 78:37-44.
13. Aoki Y, Watanabe M, Amikura T. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecol Oncol 2004; 94:333-339.
14. Kodama J, Seki N, Ojima Y. Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. Eur J Obstet Gynecol Reprod Biol 2006; [Epub ahead of print]. Adjuvant chemotherapy might improve the survival rates of histologic grade 3 endometrial cancers.
15. Sagae S, Udagawa Y, Susumu N. JGOG2033: randomized phase III trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma [abstract]. J Clin Oncol 2005; 23:16S.
16. Berek JS, Hacker NF. Practical Gynecologic Oncology. Philadelphia: Lippincott Williams & Wilkins; 2005.
17. Hamilton CA, Cheung MK, Osann K. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006; 94:642-646.
18. Sutton G, Axelord JH, Bundy BN. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006; 100:349-354. Systemic chemotherapy or chemoradiotherapy should be considered in future adjuvant trials for serous or clear cell endometrial carcinoma.
19. Kelly M, O'Malley DM, Hui P. Improved survival in surgical stage I patients with uterine papillary serous carcinomas (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005; 98:353-359. Platinum-based chemotherapy improves the survival of patients with stage I uterine papillary serous carcinoma and vaginal cuff radiation provides a good local control.
20. Hamilton CA, Liou WS, Osann K. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys 2005; 63:839-844. Adjuvant chemotherapy or radiotherapy improves the survival of patients with early stage uterine papillary serous carcinoma.
21. Randall ME, Filiaci VL, Muss H. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2006; 24:36-44. Chemotherapy improves overall survival compared with whole-abdominal irradiation in patients with advanced stage endometrial carcinoma.
22. Bruzzone M, Miglietta L, Franzone P. Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. Gynecol Oncol 2004; 94:345-352.
23. Giorgia M, Patrizia DM, Beatrice S. Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings. MBC Cancer 2006; 6:198.
24. Duska LR, Berkowitz R, Matulonis U. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with 'high-risk' endometrial cancer. Gynecol Oncol 2005; 96:198-203.
25. Greven K, Winter K, Underhill K. Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006; 103:155-159. Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy demonstrates excellent pelvic and distant control of disease for patients with uterine-confined endometrial cancer.
26. Humber C, Tierney J, Symonds P. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 2005; 19 Oct:CD003915.
27. Thigpen JT, Brady MF, Homesley HD. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004; 22:3902-3908.
28. Aapro MS, van Wijk FH, Bolis G. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomized study (55872) by the EORTC gynaecological cancer group. Ann Oncol 2003; 14:441-448.
29. Fleming GF, Filiaci VL, Bentley RC. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004; 15:1173-1178.
30. Fleming GF, Brunetto VL, Cella D. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22:2159-2166.
31. Katsumata N, Noda K, Nozawa S. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative study. Br J Cancer 2005; 93:999-1004.
32. van Wijk FH, Lhommé C, Bolis G, et al. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 2003; 39:78-85.
33. Akram T, Maseelall P, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 2005; 192:1365-1367.
34. Hoskins PJ, Swenerton KD, Pike JA. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001; 19:4048-4053.
35. Dimopoulous MA, Papadimitriou CA, Georgoulias V. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 2000; 78:52-57.
36. Sovak MA, Hensley ML, Dupont J. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: A retrospective study. Gynecol Oncol 2006; 2 May [Epub ahead of print].
37. Michener C, Peterson G, Kulp B. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol 2005; 131:581-584.
38. Hidaka T, Nakamura T, Shima T. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. J Obstet Gynaecol Res 2006; 32:330-337. Paclitaxel/carboplatin is a promising regimen which could be substituted for CAP, with major activity and a highly acceptable toxicity profile for the treatment of endometrial adenocarcinomas.
39. Weber B, Mayer F, Bougnoux P. What is the best chemotherapy regimen in recurrent or advanced endometrial carcinoma? Preliminary results [abstract]. Proc Am Soc Clin Oncol 2003; 22:1819.